Iranian Society of Gynecology Oncology

Document Type : Original Research Article


1 M.B.Ch.B, D.G.O, C.A.B.O.G. Department of Obstetrics and Gynecology, Al-Iraqia University, College of Medicine, Baghdad, Iraq

2 M.B.Ch.B, MD, PhD. Department of Obstetrics and Gynecology, University of Bagdad, College of Medicine, Baghdad, Iraq

3 Department of Anesthesia Techniques, Al–Nisour University College, Baghdad, Iraq

4 Medical Laboratory Techniques Department, Al-Mustaqbal University College, Babylon, Iraq


Background & Objective: An essential issue in obstetrics is the prevalence of maternal and fetal complications in pregnant women with polycystic ovary syndrome (PCOS). The purpose of the present study was to investigate the prevalence of pregnancy complications among various phenotypes of pregnant women with PCOS.
Materials & Methods: In the current study, the pregnancy period of 143 women with PCOS who were referred to the Babylon teaching hospital in Iraq in 2021 was analyzed based on their medical records. These women were separated into two groups based on their PCOS-related clinical symptoms. People in the first group possessed a severe phenotype, while those in the second group possessed a mild phenotype. SPSS version 23 was utilized for comparing maternal and fetal complications during pregnancy and for data analysis.
Results: Regarding maternal and fetal complications, there was a significant difference between the two groups regarding low birth weight (LBW) (P<0.05). In this study, there was no statistically significant difference between PCOS phenotypes and the incidence of gestational diabetes, preterm birth, or spontaneous abortion (P>0.05). In conclusion, women with a more severe phenotype are more likely to give birth to babies with low birth weight (LBW) (approximately 1.9 times).
Conclusion: In clinical considerations of pregnant women with PCOS, it appears necessary to consider the disease's phenotype as one of the factors influencing fetal outcomes.


 In clinical considerations of pregnant women with PCOS, it appears necessary to consider the disease's phenotype as one of the factors influencing fetal outcomes.


Main Subjects

1. Kelley AS, Smith YR, Padmanabhan V. A narrative review of placental contribution to adverse pregnancy outcomes in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2019;104(11):5299-315. [DOI:10.1210/jc.2019-00383] [PMID] [PMCID]
2. Zhang F-F, Zhang Q, Wang Y-L, Wang F-F, Hardiman PJ, Qu F. Intergenerational influences between maternal polycystic ovary syndrome and offspring: an updated overview. J Pediatr. 2021;232:272-81. [DOI:10.1016/j.jpeds.2021.01.018] [PMID]
3. Choudhury AA, Rajeswari VD. Polycystic ovary syndrome (PCOS) increases the risk of subsequent gestational diabetes mellitus (GDM): A novel therapeutic perspective. Life Sci. 2022(310):121069. [DOI:10.1016/j.lfs.2022.121069] [PMID]
4. D'Alterio MN, Sigilli M, Succu AG, Ghisu V, Laganà AS, Sorrentino F, et al. Pregnancy outcomes in women with polycystic ovarian syndrome (PCOS). Minerva Obstet Gynecol. 2021. [DOI:10.23736/S2724-606X.21.04758-4] [PMID]
5. Ahmadi S, Farahani K, Aklamli M, Ahmadi K, Beheshti N. Spinal Analgesia in Labor on Maternal and Neonatal Outcomes: A Retrospective Cross Sectional Study. J Obstet Gynecol Cancer Res. 2022;7(3):186-91. [DOI:10.30699/jogcr.7.3.186]
6. Rosenfield RL, Ehrmann DA. The pathogenesis of polycystic ovary syndrome (PCOS): the hypothesis of PCOS as functional ovarian hyperandrogenism revisited. Endocr Rev. 2016;37(5):467-520. [DOI:10.1210/er.2015-1104] [PMID] [PMCID]
7. Dewailly D, Hieronimus S, Mirakian P, Hugues J-N, editors. Polycystic ovary syndrome (PCOS). Ann Endocrinol; 2010. [DOI:10.1016/j.ando.2009.12.003] [PMID]
8. Kahsar-Miller MD, Nixon C, Boots LR, Go RC, Azziz R. Prevalence of polycystic ovary syndrome (PCOS) in first-degree relatives of patients with PCOS. Fertil Steril. 2001;75(1):53-8. [DOI:10.1016/S0015-0282(00)01662-9] [PMID]
9. Patel S. Polycystic ovary syndrome (PCOS), an inflammatory, systemic, lifestyle endocrinopathy. J Steroid Biochem Mol biol. 2018;182:27-36. [DOI:10.1016/j.jsbmb.2018.04.008] [PMID]
10. Sam S, Dunaif A. Polycystic ovary syndrome: syndrome XX? Trends Endocrinol Metab. 2003;14(8):365-70. [DOI:10.1016/j.tem.2003.08.002] [PMID]
11. Viswanathan S, Jiji R, Nayana BC, Baby C. Pregnancy complications associated with polycystic ovary syndrome: A cross sectional study. World J Pharm Res. 2022;11(5):1539-52.
12. Zademodares S, Abbaspour M, Anbarluei M, Rahmati N, Fathi M, Naeiji Z. In vitro Fertilization outcome in Patients with Polycystic Ovary Syndrome: Role of Age and Maternal Body Weight. J Obstet Gynecol Cancer Res. 2021;6(4):161-6. [DOI:10.30699/jogcr.6.4.161]
13. Willging MM, Abbott DH, Dumesic DA. Intergenerational Implications of PCOS. Polycystic Ovary Syndrome: Springer; 2022. p. 555-76. [DOI:10.1007/978-3-030-92589-5_27]
14. Grindheim S, Ebbing C, Karlsen HO, Skulstad SM, Real FG, Lønnebotn M, et al. Metformin exposure, maternal PCOS status and fetal venous liver circulation: A randomized, placebo-controlled study. PloS One. 2022;17(1):e0262987. [DOI:10.1371/journal.pone.0262987] [PMID] [PMCID]
15. Benito E, Gómez-Martin JM, Vega-Piñero B, Priego P, Galindo J, Escobar-Morreale HF, et al. Fertility and pregnancy outcomes in women with polycystic ovary syndrome following bariatric surgery. J Clin Endocrinol Metab. 2020;105(9):e3384-e91. [DOI:10.1210/clinem/dgaa439] [PMID]
16. Feigl S, Obermayer-Pietsch B, Klaritsch P, Pregartner G, Herzog SA, Lerchbaum E, et al. Impact of Thyroid Function on Pregnancy and Neonatal Outcome in Women with and without PCOS. Biomedicines. 2022;10(4):750. [DOI:10.3390/biomedicines10040750] [PMID] [PMCID]
17. Andræ F, Abbott D, Stridsklev S, Schmedes AV, Odsæter IH, Vanky E, et al. Sustained maternal hyperandrogenism during PCOS pregnancy reduced by metformin in non-obese women carrying a male fetus. J Clin Endocrinol Metab. 2020;105(12):3762-70. [DOI:10.1210/clinem/dgaa605] [PMID] [PMCID]
18. Stokkeland LMT, Giskeødegård GF, Ryssdal M, Jarmund AH, Steinkjer B, Madssen TS, et al. Changes in serum cytokines throughout pregnancy in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2022;107(1):39-52. [DOI:10.1210/clinem/dgab684] [PMID] [PMCID]
19. Fougner SL, Vanky E, Løvvik TS, Carlsen SM. No impact of gestational diabetes mellitus on pregnancy complications in women with PCOS, regardless of GDM criteria used. PloS One. 2021;16(7):e0254895. [DOI:10.1371/journal.pone.0254895] [PMID] [PMCID]
20. Wang D, Chu T, Yu T, Zhai J. Is early-follicular long-acting GnRH agonist protocol an alternative for patients with polycystic ovary syndrome undergoing in vitro fertilization? Reprod Biol Endocrinol. 2022;20(1):1-9. [DOI:10.1186/s12958-022-01007-z] [PMID] [PMCID]
21. Group REASPCW. Revised 2003 consensus on diagnostic criteria and long‐term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod. 2004;19(1):41-7. [DOI:10.1093/humrep/deh098] [PMID]
22. Khan MJ, Ullah A, Basit S. Genetic basis of polycystic ovary syndrome (PCOS): current perspectives. Appl Clin Genet. 2019;12:249. [DOI:10.2147/TACG.S200341] [PMID] [PMCID]
23. Kandaraki E, Chatzigeorgiou A, Livadas S, Palioura E, Economou F, Koutsilieris M, et al. Endocrine disruptors and polycystic ovary syndrome (PCOS): elevated serum levels of bisphenol A in women with PCOS. J Clin Endocrinol Metab. 2011;96(3):E480-E4. [DOI:10.1210/jc.2010-1658] [PMID]
24. Hussein MR, Ahmed DK. Maternal and Fetal Outcome in Patients with History of Polycystic Ovary Syndrome. Indian J Med Forensic Med Toxicol. 2019;13(4). [DOI:10.5958/0973-9130.2019.00319.0]
25. Gan Y, Lu D, Yan C, Zhang J, Zhao J. Maternal polycystic ovary syndrome and offspring birth weight: a Mendelian randomization study. J Clin Endocrinol Metab. 2022;107(4):1020-9. [DOI:10.1210/clinem/dgab843] [PMID]
26. Kim K-W. Unravelling Polycystic Ovary Syndrome and Its Comorbidities. J Obes Metab Syndr. 2021;30(3):209. [DOI:10.7570/jomes21043] [PMID] [PMCID]
27. Ferriman D, Gallwey J. Clinical assessment of body hair growth in women. J Clin Endocrinol Metab. 1961;21(11):1440-7. [DOI:10.1210/jcem-21-11-1440] [PMID]
28. Stokkeland LMT. Cytokine profiling as a measure of immunological development and deviation throughout pregnancy in healthy women and women with PCOS. 2022.
29. Vanky E, Løvvik TS. Polycystic ovary syndrome and pregnancy-From a clinical perspective. Curr Opin Endocr Metab Res. 2020;12:8-13. [DOI:10.1016/j.coemr.2020.01.005]
30. Dumesic DA, Hoyos LR, Chazenbalk GD, Naik R, Padmanabhan V, Abbott DH. Mechanisms of intergenerational transmission of polycystic ovary syndrome. Reproduction. 2020;159(1):R1-R13. [DOI:10.1530/REP-19-0197] [PMID] [PMCID]
31. Katsigianni M, Karageorgiou V, Lambrinoudaki I, Siristatidis C. Maternal polycystic ovarian syndrome in autism spectrum disorder: a systematic review and meta-analysis. Mol Psychiatry. 2019;24(12):1787-97. [DOI:10.1038/s41380-019-0398-0] [PMID]
32. Valdimarsdottir R, Wikström A-K, Kallak TK, Elenis E, Axelsson O, Preissl H, et al. Pregnancy outcome in women with polycystic ovary syndrome in relation to second-trimester testosterone levels. Reprod Biomed Online. 2021;42(1):217-25. [DOI:10.1016/j.rbmo.2020.09.019] [PMID]
33. Zhang B, Wei D, Legro RS, Shi Y, Li J, Zhang L, et al. Obstetric complications after frozen versus fresh embryo transfer in women with polycystic ovary syndrome: results from a randomized trial. Fertil Steril. 2018;109(2):324-9. [DOI:10.1016/j.fertnstert.2017.10.020] [PMID]
34. Chen X, Koivuaho E, Piltonen TT, Gissler M, Lavebratt C. Association of maternal polycystic ovary syndrome or anovulatory infertility with obesity and diabetes in offspring: a population-based cohort study. Hum Reprod. 2021;36(8):2345-57. [DOI:10.1093/humrep/deab112] [PMID] [PMCID]
35. Kollmann M, Obermayer-Pietsch B, Lerchbaum E, Feigl S, Hochstätter R, Pregartner G, et al. Vitamin D Concentrations at Term Do Not Differ in Newborns and Their Mothers with and without Polycystic Ovary Syndrome. J Clin Med. 2021;10(3):537. [DOI:10.3390/jcm10030537] [PMID] [PMCID]
36. Valdimarsdottir R, Valgeirsdottir H, Wikström A-K, Kallak TK, Elenis E, Axelsson O, et al. Pregnancy and neonatal complications in women with polycystic ovary syndrome in relation to second-trimester anti-Müllerian hormone levels. Reprod Biomed Online. 2019;39(1):141-8. [DOI:10.1016/j.rbmo.2019.02.004] [PMID]
37. Feferkorn I, Badeghiesh A, Mills G, Baghlaf H, Dahan M. The effects of smoking on pregnancy risks in women with polycystic ovary syndrome: a population-based study. Hum Reprod. 2021;36(9):2549-57. [DOI:10.1093/humrep/deab145] [PMID]
38. Valgeirsdottir H, Sundström Poromaa I, Kunovac Kallak T, Vanky E, Akhter T, Roos N, et al. Polycystic ovary syndrome and extremely preterm birth: A nationwide register-based study. PloS One. 2021;16(2):e0246743. [DOI:10.1371/journal.pone.0246743] [PMID] [PMCID]